Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G1GP
|
|||
| Former ID |
DNC001824
|
|||
| Drug Name |
ISIS 2922
|
|||
| Synonyms |
Formivirsen sodium; 5'-d[G*C*G*T*T*T*G*C*T*C*T*T*C*T*T*C*T*T*G*C*G*]-3'; 5-SpG SpC SpG SpT spT SpT spG spC spT spC spT spT spC spT spT spC spT spT spG spC spG-3'
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Cytomegalovirus infection [ICD-11: 1D82] | Withdrawn from market | [1], [2] | |
| Company |
Isis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytomegalovirus DNA polymerase messenger RNA (CMV DNA polymerase mRNA) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002227) | |||
| REF 3 | US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.